24613-06-7

Basic information

• Product Name: ICRF-186
• Synonyms: 4,4'-[(R)-1-Methyl-1,2-ethanediyl]bis(2,6-piperazinedione);ICRF-186
• CAS NO: 24613-06-7
• Molecular Formula: C11H16 N4 O4
• Molecular Weight: 268.2691
• Mol File: 24613-06-7.mol

Chemical Properties

• Boiling Point: 531.5°Cat760mmHg
• Flash Point: 275.3°C
• Appearance: /
• Density: 1.333g/cm³
• CAS DataBase Reference: ICRF-186(CAS DataBase Reference)
• NIST Chemistry Reference: ICRF-186(24613-06-7)
• EPA Substance Registry System: ICRF-186(24613-06-7)

Safety Data

• Hazardous Substances Data: 24613-06-7(Hazardous Substances Data)

Upstream product

• 4408-81-5 1,2-diaminopropane-N,N,N',N'-tetraacetic acid 
• 1029441-44-8 (S)-1,2-diaminopropane-N,N,N',N'-tetraacetic acid methyl ester 
• 21416-67-1 razoxane 
• 15250-41-6 (S)-N,N,N',N'-tetrakis[(hydroxycarbonyl)methyl]-1,2-diaminopropane 
• 1029441-45-9 (S)-N,N,N',N'-tetrakis[(ethoxycarbonyl)methyl]-1,2-diaminopropane 

Downstream Products

• 75459-34-6 ADR-925 
• 75459-34-6 ADR-925 

Relevant articles and documents

Preparation method of dexrazoxane

The invention aims to provide a simple and efficient preparation method of dexrazoxane. According to the present invention, 1, 2-propane diamine is adopted as an initial raw material, splitting is performed to obtain hydrochloride of (S)-1, 2-propane diamine, the hydrochloride and bromoacetate are subjected to condensation to prepare (S)-1, 2-diaminopropane-tetraacetate, amide is adopted as an ammonia source, and dexrazoxane is finally prepared. The method has advantages of high yield, mild reaction conditions, easy operation and less environmental pollution, and is beneficial to large-scale industrial production.

Dexrazoxane preparation method

The invention discloses a dexrazoxane preparation method. According to the preparation method, (S)-1,2-diaminopropane-tetraacetate and alkali metal salt thereof are used as raw materials, and ammoniumsalt is used as an ammonium source to prepare dexrazoxane. By the adoption of the preparation method, tedious technological operation is avoided, the technological operation is easier and more convenient, and therefore the preparation method is more adaptive to industrial amplifying production.

Dexrazoxane preparation method

The invention belongs to the field of drug synthesis, and provides a completely-new dexrazoxane preparation method, which comprises: carrying out a reaction on (S)-1,2-propanediamine ditartrate splitby using inexpensive and easily-available (+/-)-1,2-propanediamine as a starting raw material and using D-(-)-tartaric acid as a splitting agent and potassium chloride to obtain (S)-1,2-propanediaminedihydrochloride, carrying out condensation on the (S)-1,2-propanediamine dihydrochloride and chloroacetic acid to prepare (S)-N,N,N',N'-1,2-propanediaminetetraacetic acid, and finally carrying out cyclization to obtain dexrazoxane, wherein the total yield is 38.3%. According to the present invention, the route has advantages of simple reaction step, convenient post-treatment, no requirement of column chromatography separation, good product quality and the like.

Preparation method of piperazine diketone type compound

The invention discloses a method for preparing a piperazine diketone type compound and specifically relates to a method for preparing a compound shown as a formula (I) by cyclization after substitution. The method takes (S)-1,2-diaminopropane tartrate, haloacetic acid and low-carbon alcohol as raw materials to prepare the compound shown as the formula (I). Compared with the prior art, a pluralityof disadvantages are improved and overcome by the preparation method; the preparation method has the advantages of simple steps, low cost, convenience for post-treatment, cleanness, high yield and purity, low toxicity and less pollution, and industrial production is facilitated.

Synthesis of chiral carbosilane dendrimers with L-cysteine and N-acetyl-L-cysteine on their surface and their application as chiral selectors for enantiomer separation by capillary electrophoresis

The synthesis of chiral carbosilane dendrimers functionalized with cysteine and N-acetylcysteine groups is presented. These dendrimers were obtained through thiol–ene addition reactions and their application as chiral selectors in capillary electrophoresis was investigated. Four drugs used as model compounds were analyzed under different experimental conditions observing that the use of a first generation dendrimer containing 4 terminal N-acetyl-L-cysteine groups enabled the enantiomeric discrimination of razoxane with a discrimination power similar to that obtained with other powerful chiral selectors such as cyclodextrins.

A right propylimine preparation method

The invention relates to a preparation method of dexrazoxane. In allusion to various problems of a present dexrazoxane synthetic route, such as complexity, high cost, high reaction temperature, low yield, tedious aftertreatment, long production cycle and the like, the invention provides a simple and efficient preparation method of dexrazoxane. Starting from (S)-1,2- diaminopropane hydrochloride or (S)-1,2-diaminopropane, only two steps are required to obtain a crude product dexrazoxane with the highest purity of 99.46%; and simple recrystallization is carried out to obtain a pure product with purity of 99.96%. The method has advantages of simple operation and proper temperature. By the method, the cycle of synthetic process is shortened greatly. In addition, yield and purity of the product are also raised greatly.

Novel Method for Producing 4,4-(1-Methyl-1,2-Ethanediyl)-BIS-(2,6-Piperazinedione)

A method for preparing compounds of the formula (I) by the cyclization of tetraacetic acid alkyl esters of the formula (II) in the presence of ammonia and formamide as well as to the compounds of the formula (II), which are used in this method.

Prevention and treatment of cardiac conditions

The present invention provides a method of treating conditions associated with iron and calcium overload comprising administering an effective amount of dexrazoxane or a non-dexrazoxane compound of formula (IA), (IB), or (IC) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes

A process for preparing a compound of the formula (I) STR1 wherein R1 and R2 are individually selected from the group consisting of hydrogen and methyl or R1 and R2 together represent an ethylene bridge group comprising: reacting a diamine of the formula (II) where R1 and R2 are defined as above with formaldehyde and an alkaline metal cyanide at a pH in the range of about 0 to 2 to produce a tetranitrile of the formula (III): hydrating said tetranitrile to yield an acid addition salt of a tetraamide of the formula (IV): where R1 and R2 are defined as in formula (I) and X is an acid anion such as fluoride, chloride, bromide or sulfate but preferably chloride; and reacting said acid addition salt of said tetraamide in a cyclization reaction to yield said compound of the formula (I).

Bis diketopiperazines

A pharmaceutical composition useful for aiding regression and palliation of cancer in mammals comprises a therapeutically effective amount of a compound of formula EQU1 wherein R1 and R2 are each separately selected from hydrogen and methyl or together represent an ethylene bridging group, with the proviso that when both of the groups R1 and R2 are methyl they are disposed in the meso configuration, or a non-toxic salt thereof with a physiologically acceptable inorganic or organic acid, in combination with a physiologically acceptable diluent or carrier.